Monique A. Spillman - Concepedia

Author

Monique A. Spillman

University of Colorado Anschutz Medical Campus ORCID

Also Known As

Badtke, Melanie M., M A Spillman, M Spillman, M. A. Spillman, M. Spillman, M.A. Spillman, Monique A Spillman, Monique A. Spillman, Monique Spillman, Spillman, Monique

151

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Anschutz Medical Campus University of Colorado Denver Baylor University Medical Center Duke Medical Center The University of Texas Southwestern Medical Center

About

Monique A. Spillman is an author at University of Colorado Anschutz Medical Campus specializing in medicine, obstetrics, and ovarian cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	2.2K
2	Public Health	4	4	293
3	Engineering	1	1	95
4	Health Sciences	1	1	291
5	Natural Sciences	1	1	746

Monique A. Spillman

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Identification of a RING protein that can interact in vivo with the BRCA1 gene product Leeju C. Wu, Zhuo Wei Wang, Julia Tsou Tsan, Nature Genetics Natural SciencesProtein GeneticsMolecular BiologyGene CharacterizationMolecular Genetics	1996	746
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Gail E. Tomlinson, Thomas T. Chen, Victor Stastny, PubMed Breast OncologyCancer PathologyPathologyCancer BiologyTumor Biology	1998	291
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research Michael S. Anglesio, Kimberly C. Wiegand, Nataliya Melnyk, PLoS ONE	2013	245
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination Christopher Korch, Monique A. Spillman, Twila A. Jackson, Gynecologic Oncology InfertilityMedicineGeneticsReproductive HealthDna Analysis	2012	243
Frequent <i>IGF2/H19</i> Domain Epigenetic Alterations and Elevated <i>IGF2</i> Expression in Epithelial Ovarian Cancer Susan K. Murphy, Zhiqing Huang, Yaqing Wen, Molecular Cancer Research	2006	131
Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel Diana M. Cittelly, Irina Dimitrova, Erin N. Howe, Molecular Cancer Therapeutics Endocrine-related CancerMedicineTumor BurdenTumor ImmunityGynecology	2012	124
BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Monique A. Spillman, A. Bowcock PubMed	1996	123
A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells Kun Zhou, Kevin W. Diebel, Jon Holy, Oncotarget EngineeringCancer BiologyTumor BiologyOvarian CancerBcar3 Expression	2017	95
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial Ignace Vergote, Giovanni Scambia, David M. O’Malley, The Lancet Oncology Advanced Ovarian CancerMedicinePharmacologyGynecologyFirst-line Treatment	2019	85
CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer Zachary L. Watson, Lubna Qamar, Tomomi M. Yamamoto, Oncogenesis	2018	83

Page 1